Comparative Pharmacology
Head-to-head clinical analysis: POLYCILLIN PRB versus TRIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYCILLIN PRB versus TRIMOX.
POLYCILLIN-PRB vs TRIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours depending on infection severity.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Terminal elimination half-life: 1-1.5 hours (normal renal function); in renal impairment (CrCl <10 mL/min), extends to 6-20 hours, requiring dose adjustment.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Renal: 50-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minimal, <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic